Genmab A (GMAB) Receivables (2023 - 2025)

Genmab A's Receivables history runs 3 years deep, the most recent figure standing at $1.2 billion for Q4 2025.

• Quarterly Receivables rose 22.17% year-over-year to $1.2 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 billion (up 22.17% YoY) and the FY2025 annual result came in at $1.2 billion, up 22.17% from the prior year.
• Receivables was $1.2 billion for Q4 2025 at Genmab A, up from $979.0 million in the prior quarter.
• Across five years, Receivables topped out at $1.2 billion in Q4 2025 and bottomed at $786.0 million in Q4 2023.
• A 3-year average of $987.0 million and a median of $979.0 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2024 — Receivables climbed 24.55% — and 2025, when it gained 22.17%.
• Genmab A's Receivables stood at $786.0 million in 2023, then advanced by 24.55% to $979.0 million in 2024, then climbed by 22.17% to $1.2 billion in 2025.
• Business Quant data shows GMAB's Receivables at $1.2 billion in Q4 2025, $979.0 million in Q4 2024, and $786.0 million in Q4 2023.